Axsome Therapeutics Earnings & Forecasts

Axsome Therapeutics (AXSM) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Aug 10, 2026	$-0.99	$-0.87	-13.8 %
Q1	May 4, 2026	$-1.26	$-0.83	-51.8 %
Q4	Feb 23, 2026	$-0.56	$-0.72	22.2 %
Q3	Nov 3, 2025	$-0.68	$-0.87	21.8 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Aug 10, 2026	$218.40M	$222.33M	-1.77 %
Q1	May 4, 2026	$191.20M	$190.28M	0.48 %
Q4	Feb 23, 2026	$196.00M	$193.16M	1.47 %
Q3	Nov 3, 2025	$170.99M	$163.41M	4.64 %

Axsome Therapeutics Guidance

Axsome Therapeutics (AXSM)는 1월 4, 2024에 fiscal year 2023에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $204M - $204M 범위로 예상했습니다.

이전 가이던스와 비교하여 Axsome Therapeutics는 매출 전망치를 이전 범위인 상향 조정됨에서 $71M - $71M로 상향 조정했습니다.

Axsome Therapeutics은 2과 1월 4, 2024 사이에 1월 4, 2024개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.87	$-0.83	$-0.72	$-0.87
Actual	$-0.99	$-1.26	$-0.56	$-0.68
Surprise	-13.8%	-51.8%	+22.2%	+21.8%
Revenue
Estimate	$222.3M	$190.3M	$193.2M	$163.4M
Actual	$218.4M	$191.2M	$196.0M	$171.0M
Surprise	-1.77%	+0.48%	+1.47%	+4.64%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.49	$0.02	$-0.08	$0.49
Revenue
Consensus	$257.5M	$296.5M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.

Avi Kapoor

PRO
Axsome Therapeutics Q2 EPS $(0.99) Misses $(0.83) Estimate, Sales $218.400M Miss $221.230M Estimate

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.83) by 19.28 percent. This is a 110.64 percent decrease over losses of $(0.47) per

Benzinga Newsdesk

Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock

Axsome (AXSM) Q1: Revenue beats, but wider loss and rising expenses weigh on shares. Get the key data on Sunosi and Auvelity sales.

Vandana Singh

Earnings Scheduled For May 4, 2026

Benzinga Insights

PRO
Axsome Therapeutics Q1 EPS $(1.26) Misses $(0.90) Estimate, Sales $191.203M Beat $189.193M Estimate

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.90) by 40 percent. This is a 85.29 percent decrease over losses of $(0.68) per share

Benzinga Newsdesk

PRO
Axsome Therapeutics Q4 EPS $(0.56) Beats $(0.68) Estimate, Sales $195.999M Beat $193.107M Estimate

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.68) by 17.4 percent. This is a 30 percent increase over losses of $(0.80) per share from

Benzinga Newsdesk

Axsome Therapeutics Inc